High-content screening is a powerful technology platform for implementing functional cell-based assays that allow truly multi-parametric analysis in the physiological context of intact cells. This course provides an introductory level overview of the state-of-the-art components of HCS together with some showcases of high-content screens in industry and academia.
Those interested in the following tracks:
The course will provide:
Eberhard Krausz is working for VIB, a more than 1500 scientists counting life science research organisation in Flanders, Belgium, translating basic research outcomes into early drug discovery programmes. Since 2008, he has been supporting scientists during various positions in industry and academia in technology selection, target identification & validation, assay development & screening, and drug discovery. In 2003-2008, he was heading the central high-content screening labs at the Max Planck Institute in Dresden, Germany. Before, he held responsible positions in biotech industry at Cenix BioScience (Germany) and Cyclacel (Scotland, UK) dealing with RNA interference (RNAi) and drug discovery, respectively.
Steffen Jaensch works at Janssen R&D, Pharmaceutical Companies of Johnson & Johnson in Beerse, Belgium. Since 2011 he is responsible for the analysis of high-content assay development and screening projects for drug discovery, target identification and phenotypic compound characterization. His current focus is on the development of compound profiling methods for target predictions based on multi-parametric analysis of high-content imaging data. He earned his Ph.D. at the Max-Planck-Institute CBG in Dresden, Germany, and HHMI Janelia Farm research campus in Ashburn, USA, developing image analysis algorithms for studying centrosome dynamics in C. elegans embryos. By training he is a computer scientist.